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Monoclonal antibody PAL-M 1, which was selected to dis-
criminate between nevocellular nevi and cutaneous mela-
nomas, has not been characterized until now. Here we show 
that PAL-M 1 i~ directed against the transferrin receptor 
{CD71). The molecules precipitated by PAL-Ml and by 
anti-transferrin receptor antibodies OKT9 and 5E9 from 
various human rumor cell lines {melanoma, hepatoma, and 
lymphoma) show identical characteristics on SDS-PAGE. 
M elanoma ant1gens that are preferenually expre~sed 111 one or more stages of tumor progress1on have been named melanoma-associated progreSSion anugem [ 1-8]. Based on molecular clonmg [9,10], ~ome o( these antigens were idenufied as 
biolog1cally relevant molecules. Examples of such anugens ar<.' HLA 
class llmol<.'cub, wh1ch play an important role in the generation of 
cellular immune responses, and the cell-adhesion molecule, 
ICAM-1. Recently it wa~ proposed that ICAM-1 could hav(.' an 
important role in melanoma metastasis [t 1]. The monoclonal anti-
body (MoAb) PAL-M I, wl11Ch was selected todiscnminatc berween 
mahgnant cutaneous melanoma and nevocellular nevi [ 1], also 
identified a melanoma progreSSion antigen. Because of the Impor-
tance of the proce~s of tumor progression, we decided to further 
charactenze the chem1cal structure and the b1ologtc role of the 
PAL-M1 anttgen. Here we show that PAL-M1 recogmzes the 
transfernn receptor (TFR, CD71) and rhat TFR IS a marker for 
rumor progremon 111 the mclanocytic lineage. 
Manuscnpr recetved Sc.-prembc.-r 22, 1989; accepted for publtcanon March 
6, 1990 
Tht~ work was supported hy a grant from the Dutch Cancer Soctery .tnd 
from rhe Dcut,che KrehshilrC', Mildred Scheel Stiftung. 
Repnnt requcm to: Dr. G.N.P. van Mutjen, Department of Pathology. 
Untvermy Hosptral Numegcn; P.O . .Box 9101,6500 Hl:l NiJmegen, The 
Netherlands. 
Ahhrevt3ttom: 
DN: dyspl.l~nc nevm 
FITC: fluore~cem tsothlocyanate 
HRPO: honeradtsh perox;dase 
I CAM-I. tntercellular adheston molecule-1 
MM· melanoma merasta~IS 
NN: nevocdlular nevus 
PM: pnmary melanoma 
SDS-PAGE: sodmm dedecvl sulfate polyacrylamtde gel electrophorests 
TFR: trJmfemn receptor 
PAL-Mt also specifically recognized mouse L cells express-
ing the human transferrin receptor gene. Competition ex-
periments demonstrated that PAL-M 1 and OKT9 recognize 
the same or a spatially close determinant. Immunohistoche-
mical staining of a large series of melanocytic lesions indi-
cates that the transferrin receptor can be considered as a pro-
gression antigen in this type of lesion. J ltwest Dermatol 
95:65-69, 1990 
MATERIALS AND METHODS 
Cell Lines Human tumor cell lmes used were as follows-
melanoma: Me IS7 [12], CMell36 [13], M 14 (14], and BLM [ISl; 
hepatoma: HepG2 [16] and PLC/RPF [17]; lymphoma: Daudi [18 , 
and RaJi f 19]. Murine cell lines Ltk- cells and E I 0.2 expressing the 
human TFR gene [20] were kindly provided by Dr. L. Kuhn, 
ISREC, Lausanne, Switzerland. The E I 0.2 cells were maintained in 
HAT medium. All melanoma and hepatoma cell lines were cultured 
at 37"C with S% C02 in DMEM with 10% FCS, 2 mM L-gluta-
mme, SO IU jml penicillin, and SO ,ug/ml streptomycin. Cultured 
lymphoid cell lines and EBV transformed peripheral blood lympho-
cytes (PBL) and Ltk- cells were grown in RPMI-1640 medium 
contaimng the same supplements as the hepatoma and melanoma 
cell hnes plus 1 mM pyruvate. 
Cytospio Preparations and Monoclonal Antibodies Mono-
lay<.'r cultures of hepatoma and melanoma cell lines were detached 
from culture flasks by treatment With O.S mM EDT A in PBS. Cell 
susp<.'nSIOns were washed 3 times with PBS containmg 30/o BSA. 
Fmally, 2-4 X 104 cells were cenmfuged (ISO X g) on coverslips at 
room temperature. Monoclonal anubodies used were as follows: 
PAL-M I [I]; OKT9 (21 ]. 5E9 [22]. and 786 (P. Reiber, Institute for 
Immunology, Munich, FRG). All these MoAb arc directed against 
the transf<.'rrin reccpror. W6.32 [23]1s directed against the back-
bone of HLA class I antigens. 141.11 (G. Hammerling, German 
Cancer Center, Heidelberg, FRG) is directed against H-2Kk. 
B8.1 1.2 [24] and L243 (25] arc directed against HLA-DR antigen. 
PAL-Ml, OKT9, B8.11.2, and 5E9 are IgGl, 786 and 141.11 are 
IgM, and W6.32 and L243 arc lgG2a. 
RadiolabeHng of Cells and lmmunoprecipitatioo Cell lines 
grown a~ monolayers were first harvested by incubatton with 
0.5 mM EDTA in PBS. Cell suspensiOns were surface labeled with 
125Na l (Amersham, England) by the lactoperoxidase technique [26]. 
lmmunoprec1pitauon was performed as previously described 
[27]. Briefly, following precleanng of rad10acuve-labeled cell lysate 
w1th protem A-Sepharose (Pharmac1a, Sweden) coated with affin-
Ity-purified rabbit-anti-mouse lg, 1-10 X 106 cpm were incu-
bated for I h ar 37"C w1th e1ther S-10 ,ul of asCites fluid or 100-
0022-202X/90/S03.50 Copynght © I 990 hy The Soctery for lnvesnganve Dem1atology, Inc. 
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200 ,ul of msue-culture >upernaranr from hybridoma cells. Immune 
complexes were precipitated by a 2-h incubation on a rotator at 
37"C with 50 ,ul of protem A-Sepharose beads coated With rabbit-
ann-mouse Ig antibodies. Immune complexes were released from 
the heads by bo.Img m Laemmli's SDS-PAGEsample buffer wah or 
Without OTT as reducmg agent and analyzed on 10% PAGE [28]. 
Gels contammg 1251-laheled components were fixed, dried, and ex-
pmed directly to x-ray films (Eastman Kodak, The Netherlands) at 
-70 C usmg mtens1fymg screens. 
F low Cytom et ry Murine L cells (Ltk-) and the TFR-expressmg 
transfectant El 0.2 (20] were analyzed for MoAb binding with mdi-
rect unmunoAuorescence. The cells were incubated with MoAb as 
undiluted tissue-culture supernatant or purified antibody at 20 
J1g/ml. Following incubation with FITC-conjugated rabbit ann-
mouse rmmunoglobuhn (F261 Dakop:ms, Denmark), the cells 
were washed, fixed m 0.1 o/o para formaldehyde, and analyzed in a 
FACSCAN (Becron-D1ekmson, Mountain View, CA). 
Competition Exper im ents To determine whether the 
PAL-M I epitopc can be blocked by anti-transferrin receptor anti-
bodies, competition experiments were done on cytospm prepara-
tions of TFR-posmve melanoma and hepatoma cell lmes. After 
fixation. cells were mcubated with different MoAb for 1-2 h at 
room temperanrre, washed, and incubated directly w1th 
horserad1sh-peroxidase-labeled PAL-Ml antibody (PAL-Ml-
HRPO) for I hat room temperature. Binding of PAL-M 1-I IRPO 
was visualized by mcubanon with 3-amino-9 ethylcarbazole as sub-
strate. Harns hematoxylm was used to counterstain. 
T issues a nd Im munocytochemical Staining Samples of 40 
nevocellular nev1 (NN), 48 dysplastic nevi (DN), 31 primary mela-
nomas {PM), and 34 melanoma metastases (MM) were removed 
from fresh surg•cal matenal, snap-frozen, and stored at -7o•c. 
Samples were clamfied on the basis of histopathologic exammanon 
of paraffin sections. 
Indirect immunoperoxidasc staining was done w1th ussue-cul-
ture supernatants on cytospin preparations and frozen tissue secuons 
after acetone fixauon as described by Nakane and P1erce [29]. 
Rabb1t-ann-mouse Ig conJugated to horserarush perox1da~e (Da-
kopam, Denmark) was used as the second antibody, and 3-ammo-
9-ethylcarbazole was used as substrate. Harris hematoxylm {Merck, 
FRG) was employed for counterstainmg. For tmmunoAuorescence, 
FITC-labcled sheep-anti-mouse Ig (Dakoparrs, Denmark) was 
u\ed as second amibody. 
RESULTS 
Exammation of a number of different cell lines for reactiviry w1th 
the PAL-MI ami body revealed that expression of this antigen 1s not 
restricted to melanoma cells. In fact, positive staining was seen With 
all cell lines twed: Mel 57, CMel136, M 14, and BLM (all mela-
noma cell lines); HepG2 and PLC/RPF {hepatoma cell lines); 
Daudi and Raj• (lymphoma cell lines), and EBV-transformcd PBL. 
The percentage of positive cells was 80- 100% in all cell lines tested 
except rhe HepG2 and Daudi cell lines (<50%). Immunofluores-
cence on non-fixed cells showed that the PAL-Ml antibody was 
directed agaum a cell-surface antigen. 
A senes of immunocytochemical stammgs on a number of 
PAL-M 1 pomive cell hnes with anti-TFR MoAb OKT9 showed 
nearly 1denncal stammg results. The only difference was that, in 
general, the s•gnal was somewhat stronger with OKT9. 
Analys•s of PAL-MI unmunoprecipitates prepared from 1251-la-
beled melanoma cell lines revealed a molecule with an apparent 
molecular wctght of200 kD under non-reducing and 95 kD under 
reducing condinons (Fig I). These observations suggested that the 
PAL-MI MoAb may recognize the transferrin receptor. In v1cw of 
these findmgs, we also performed 1mmunoprecipitation experi-
ments with other anti-TFR anribodies, especially OKT9. 
Figure Ia shows the rmmunoprecipitation results an,1lyzed under 
non-reducing conditions. As can be seen, specific bands were local-
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Figure 1. Auroradtograph of a IOo/o SDS-PAGE under non-reducing (a) 
~nd reducmg (b) condinons. Lants 2 and J show unmunoprec1pitatcs of M 14 
me-lanoma cells with PAL-MI (/ants 2} and OKT9 (lantJ 3). LantS 4 and 5 
show 1mmunoprecrpitates of PLC/RPF hepatoma cells wtth PAL-M I (/antS 
5) and OKT9 (/ants 4}. Lano I (M14 cells) and 6 (PLC/RPF cells) arc 
ncganve controls. 
1zed at 200 kD and 400 kD (dimer) both w1th theM 14 melanoma 
celllme and the PLC/RPF hepatoma !me. Idenncal immunoprecip-
ttanons analyzed under reducing conditions are shown in Fig 1 b. 
Spwfic bands were shifted from 200 kD to 95 kD in both cell lines 
tested and identical patterns were obtamed for PAL-M 1 and O KT9, 
wh1ch strongly suggests that PAL-M 1 is directed against TFR. 
To directly test whether PAL-M 1 reacts with TFR, mouse L cells 
expressing the human TFR gene were examined. As shown in Fig 2, 
PAL-M I, SE9, and 766 all hind to the TFR-exprcssing transfectant 
{EIO) but not to the Ltk- cell. MoAb 141.1 1, directed against the 
mouse H-2Kk, served as a pos•tive control for both cells, whereas 
L243, detecnng HLA-DR. served a_s a negative control. 
To analyze the spatial relanonship between the determinants rec-
ogmzed by TFR antibodies and that defined by PAL-M 1, cross-
blocking experiments were performed. As can be seen in Table I, 
MoAb OKT9 and PAL-M1 inhibited each other completely on 
both melanoma and hepatoma cell lines. No cross-blocking was 
seen with ocher TFR antibodies or with irrelevant a nobodies against 
HLA class I and II anngens. 
Immunohistochemical staining of PAL-M 1, OKT9, and 5E9 
were compared on a large series of melanocyuc lesions. From these 
incubations it was clear that the staming patterns with all three 
antibod1e~ were essentially identical. Figure 3 shows the proportion 
of melanocytic cells stained in all four rypes of lesions. Common 
nevi and dysplastic nevi were either negative or contained only a 
limited number of posttive cells (NN less than 5o/o and DN less than 
25%). It ~hould be noted that most of the 13 ON that were scored 111 
the 0 - 5% category had only sporadrcally (< 1%) posiuve cells. 
When we cons1dered less than 5% positive cells as negative and 5% 
or more positive cells as posmve, all {40 of 40) NN anJ 98% {47 of 
48) of the DN were neganve. Under these conditions, 70% {22 of 
31) of PM and 90% {30 of 34) MM were poSittve. 
DISCUSSION 
In tim paper we have shown by unmunochem~eal and biochemical 
analyse~ that the MoAb PAL-M 1 recogmzes TFR. In add1rion, 
competition expenments with d1fferent ann-TFR MoAb demon-
strated that PAL-M I recognizes the same or a determinant spatiaJly 
close co that defined by the OKT9 MoAb. The slight differences in 
rmmunohistochemical staming on cytospm preparations of various 
cell hnes and on frozen sections of melanocyuc lesions may reAect 
d1fferences in affimry between OKT9 and PAL-M I , or may indi-
cate that they do not recognize exactly the same determinant. 
The expressron of TFR on the cell surface IS closely associated 
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Figure 2. Reactivity of MoAb wtrl~ rn.ou~e cell.s expressmg rhe human rransf~mn re~eptor. Munne L cells (Lrk.-) and an L-c~ll uansfecunt expressing high 
levels of TFR (E I 0.2) were rested 111 mdtrect 1mmunolluoresccncc for reacttvlty wtrh the followmg annbod1es: L243 (antt-HLA-DR, used as a negative 
control). 141 .11 {antt-H2_Kk, used as a positive control). PAL-Ml . 7B6 (antt-TFR), and 5E9 (antt-TFR). Followmg MoAb incubatton, the cells were exposed 
to FITC-conJugated rabbit-ann-mouse tmmunoglobuhns and analyzed hy flow cytometry. Three thousand cells were analyzed for each sample. The x-axis 
md1cares the relmve fluorescence on a logarithrruc scale; rhe y-axu mdtcares number of crlls. The dortrd li11r marks channel 484; cells with fluorescence 
tntensiries less rhan th1s were constdered negutve. 
with cell growth [2 1 ,30- 32). H owever, the degree of expremon of 
TFR ~~. in some cells, also closely related to cell differenuatton 
[33- 36). Immunohistochemical studies concerning the dlStnbu-
uon ofTFR revealed that there is a restricted expreSSion on normal 
nssues [37 ,38]. ExpreSSion was not only seen o n cells with proltfera-
tive capacity suc h as rhe basal cell layer of the oesophageal surface 
epithelium, but also on differennated mucosal epithelium of the 
gastrointestinal tract and on non-proltferative ruhular t"pithelmm of 
the kidney. In concrast to the lumted pattern of expre~~ion in nor-
mal n ssues, TFR was widely d1srribured in carcmomas, lymphomas, 
and sarcomas [37 - 42). Several investigators have assumed that, 
based on the fact that the proltfcrative activity of a rumor is rx-
pressed by the level ofTFR expression on the cell surfacr , determi-
nation of TFR expression mtght be used as marker for tumor pro-
gression [41 ,43,44}. In several senesoflymphomas 1t was found that 
h1gh-grade lymphomas express TFR more often and mo re intensely 
than low-grade lymphomas. H owever, M edetros et al [42) recently 
reported that in a large series of D- and T-cell no n-Hodgkin's lym-
pho mas, TFR expression by cerram histologic subtypes of lym-
phoma did not correlate with the1r morpholog1c grade or w 1th 
Table I. Blocking of PAL-M 1-Epito pe by O ther Monoclonal 
Antibodies 
Cell Lin~ 
PLC/RPF 
PLC/RPF 
PLC/RPF 
PLC/RPF 
PLC/RPF 
HepG2 
HepG2 
HepG2 
HepG2 
Ml4 
Ml4 
Ml4 
M14 
Mel 57 
Mel 57 
Mel 57 
Mel 57 
Mel 57 
Fir>t MoAb 
W6.32 
PAL-MI 
OKT9 
7B6 
PAL-MI 
OKT9 
7B6 
PAL-MI 
OKT9 
7l36 
B.8.11.2 
PAL-MI 
O KT9 
7B6 
HRPO-Llbeled MoAb 
PAL-Ml 
PAL-MI 
PAL-Ml 
PAL-MI 
PAL-MI 
PAL-MI 
PAL-MI 
PAL-MI 
PAL-M I 
PAL-MI 
PAL-MI 
PAL-MI 
PAL-MI 
PAL-MI 
PAL-MI 
PAL-MI 
PAL-MI 
PAL-MI 
Blockmg 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
survival. ldenucal stud1es with lymphomas were done with bladder 
rransmonal cell carcinomas [40). It w as found that in this type of 
rumor TFR expression was related to histologic g rade and increas-
ing pathologtc stage. 
Our 1mmunohistochem1cal data strongly suggest that in melano-
cytic lesions, also, there is a clear correlation between TFR expres-
sion and stage of tumor progression. W e found a correlatio n not 
only between the type of lesions and the presence ofTFR-posit'ive 
cells, bur also between rhe proportion of melanocyric cells stained 
and the grade of malignancy: a few positive cells in benign lesions 
and many more positive cells in m alignant lesio ns. Our results are in 
agreemellt w trh rhose recentl y published by Soyer et al (45), who 
also found that all primary (I 0 cases) and metastatic (seven cases) 
malignant melanomas were OKT9 positive, whereas benign mel-
anocyttc nevi (eight cases) were al most completely negative. 
The mechantsm by which the express1on ofTFR is regulated on 
(pre)neopla~nc cells durmg rumor progression is obscure. However, 
Soro kin et al (46] reported recently some interesting data with re-
spect to TFR expressiOn. From a study in which they compared 
TFR metabolism in normal and transformed chick m yogenic cells 
40 
30 
20 
10 
0 
0 0-5 6-26 26-60 51-75 76-100 
percentage poaltlve melanocyt lc cella 
~-NN ~ ON CJ PM ~ MM l 
Figure 3. Dtagram repre;entmg the level of TFR expreSSion m dtfferent 
hum~n melanocyttc lestons. The level is mdicated as the estunated pcrcem-
age of melanocyttc cells statned. Note that the level ofTFR express1on is low 
m the belllgn and premahgnant melanocync lesions. and high m pnmary 
and mcta\tauc melanoma~. 
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they concluded that, whereas the mechanism of rransfernn and tron 
uptake wa~ the same 111 both cell rypes, there were dtlferences m 
TFR numbers and receptor function. Transformed cells contained 
more TFR, e!>pecially on the cell surface. In addttion, two different 
pathways for rransfcrnn cycling were discerned, a ~low and a fast 
pathway. The latter one was the more important 111 transformed 
myogemc cells compared wtth the non-transformed cell~. The fact 
that such dramatic differences were found in TFR expremon during 
rumor progremon suggests that similar transformation-\pecific 
characteri ~t ics also extst in other cell types. 
In conclusion, we showed that the PAL-M 1 MoAb recognizes 
TFR and that TFR ts a progremon antigen in melanocyu c lestons. 
IVr rlra11k l11r Comelrsmr a11J Ka.! jarnr11 for their expert trrlurilal asmtc111n. 
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ESSAY CONTEST 
The Jefferson Center for lnternanonal Dermatology i~ pleased to announce an essay contest 
open to re51dents in training and those within rwo years of complerion of training. Any area of 
chntcal or research dermatology 1s SUitable for this competition. The ideal essay wdl combine 
cluucal and laboratory invesuganon. Winners will be invited to present their work at the 
Caribbean Derm conference 111 March 1991. Essay should be submmed in the manuscnpt 
format of The Imemmro11al Journal •if Demratolo.~. Deadhne for submissions is October 1, 1990. 
Please send manuscnpt~ to Guy F. Webster, M.D., Ph.D., Department of Dermatology, M-46 
Jeffer~on Alumm Hall, Jefferson Medical College, I 020 Locust Street, Philadelphia, PA 19107. 
